KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vertex Pharmaceuticals (VRTX) Restructuring Costs (2016 - 2018)

Historic Restructuring Costs for Vertex Pharmaceuticals (VRTX) over the last 10 years, with Q4 2018 value amounting to -$4000.0.

  • Vertex Pharmaceuticals' Restructuring Costs fell 10103.36% to -$4000.0 in Q4 2018 from the same period last year, while for Sep 2019 it was -$4000.0, marking a year-over-year decrease of 10069.57%. This contributed to the annual value of -$184000.0 for FY2018, which is 10129.16% down from last year.
  • As of Q4 2018, Vertex Pharmaceuticals' Restructuring Costs stood at -$4000.0, which was down 10103.36% from $174000.0 recorded in Q3 2018.
  • In the past 5 years, Vertex Pharmaceuticals' Restructuring Costs registered a high of $40.8 million during Q3 2014, and its lowest value of -$3.3 million during Q1 2015.
  • Its 5-year average for Restructuring Costs is $3.4 million, with a median of $365000.0 in 2016.
  • Its Restructuring Costs has fluctuated over the past 5 years, first soared by 1576666.67% in 2014, then tumbled by 15287.65% in 2015.
  • Over the past 5 years, Vertex Pharmaceuticals' Restructuring Costs (Quarter) stood at $4.2 million in 2014, then crashed by 63.4% to $1.5 million in 2015, then plummeted by 85.3% to $224000.0 in 2016, then skyrocketed by 72.77% to $387000.0 in 2017, then crashed by 101.03% to -$4000.0 in 2018.
  • Its last three reported values are -$4000.0 in Q4 2018, $174000.0 for Q3 2018, and -$62000.0 during Q2 2018.